Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Franken, M.G.; Leeneman, B.; Jochems, A.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; ... ; Uyl-de Groot, C.A. (2018)

Article / Letter to editor

• advanced cutaneous melanoma
• colitis
• healthcare costs
• immune-related adverse events
• ipilimumab

• All authors: Franken, M.G.; Leeneman, B.; Jochems, A.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Eertwegh, A.J.M. van den; Groot, J.W.B. de; Hoeven, K.J.M. van der; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.; Kruit, W.H.J.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Suijkerbuijk, K.P.M.; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M.; Zeijl, M. van; Haanen, J.B.A.G.; Uyl-de Groot, C.A.
• Date: 2018-07-31
• Journal: Anti-Cancer Drugs
• Volume: 29
• Issue: 6
• Pages: 579 - 588
• DOI: doi:10.1097/CAD.0000000000000628